232 related articles for article (PubMed ID: 28965854)
21. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.
Gdowski AS; Ranjan A; Sarker MR; Vishwanatha JK
Nanomedicine (Lond); 2017 Sep; 12(17):2083-2095. PubMed ID: 28805551
[TBL] [Abstract][Full Text] [Related]
22. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
23. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
24. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
Lian H; Wu J; Hu Y; Guo H
Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
[TBL] [Abstract][Full Text] [Related]
25. Tumor-targeted drug delivery using MR-contrasted docetaxel - carboxymethylcellulose nanoparticles.
Ernsting MJ; Foltz WD; Undzys E; Tagami T; Li SD
Biomaterials; 2012 May; 33(15):3931-41. PubMed ID: 22369962
[TBL] [Abstract][Full Text] [Related]
26. [Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary].
Maráz A; Boér K; Dankovics Z; Dank M; Lahm E; Petrányi Á; Révész J; Ruzsa Á; Szûcs M; Valikovics A; Vas M; Küronya Z
Magy Onkol; 2017 Dec; 61(4):353-360. PubMed ID: 29257155
[TBL] [Abstract][Full Text] [Related]
27. Targeted Delivery of Cabazitaxel by Conjugation to Albumin-PEG-folate Nanoparticles Using a Cysteine-acrylate Linker and Simple Synthesis Conditions.
Khoeeniha MK; Esfandyari-Manesh M; Behrouz H; Amini M; Varnamkhasti BS; Atyabi F; Dinarvand R
Curr Drug Deliv; 2017; 14(8):1120-1129. PubMed ID: 27875950
[TBL] [Abstract][Full Text] [Related]
28. Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.
Wan Z; Xie F; Wang L; Zhang G; Zhang H
Int J Nanomedicine; 2020; 15():5333-5344. PubMed ID: 32801692
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, characterization and antitumor evaluation of CMCS-DTX conjugates as novel delivery platform for docetaxel.
Liu F; Feng L; Zhang L; Zhang X; Zhang N
Int J Pharm; 2013 Jul; 451(1-2):41-9. PubMed ID: 23608199
[TBL] [Abstract][Full Text] [Related]
30. Self-assembled Micelle Loading Cabazitaxel for therapy of Lung Cancer.
Zhuang B; Du L; Xu H; Xu X; Wang C; Fan Y; Cong M; Yin J; Li H; Guan H
Int J Pharm; 2016 Feb; 499(1-2):146-155. PubMed ID: 26762884
[TBL] [Abstract][Full Text] [Related]
31. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
32. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
[TBL] [Abstract][Full Text] [Related]
33. Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel.
Qu N; Sun Y; Xie J; Teng L
Anticancer Agents Med Chem; 2017; 17(2):294-300. PubMed ID: 27225451
[TBL] [Abstract][Full Text] [Related]
34. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
35. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
[TBL] [Abstract][Full Text] [Related]
36. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract][Full Text] [Related]
37. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
38. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Aggarwal R; Bryce A; Ryan CJ; Harzstark A; Derleth C; Kim W; Friedlander T; Lin AM; Rodvelt-Bagchi T; Dhawan M; Zhang L; Lee M; Siebeneck E; Hough J; Small EJ
Urol Oncol; 2017 Apr; 35(4):149.e7-149.e13. PubMed ID: 28161323
[TBL] [Abstract][Full Text] [Related]
39. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
40. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
